Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology.[2][3] Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.[4][5]
History
Editas Medicine was originally founded with the name "Gengine, Inc." in September 2013 by Feng Zhang of the Broad Institute, Jennifer Doudna of the University of California, Berkeley,[6] and George Church, David Liu